BioPharma Credit plc provides investors with an opportunity to gain exposure to the fast growing life sciences industry, through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. BioPharma Credit’s primary objective is to generate predictable income for shareholders over the long term
BPCR currently has ~$1.4bn invested across 10 transactions
Bristol Myers BMY $122.9m
Optinose OPTN $130.0m
Akebia AKBA $100.0m
Global Blood GBT $250.0m
Collegium COLL $625.0m
Sarepta SRPT $550.0m
LumiraDx LMDX $300.0m
Evolus EOLS $75.0m
Coherus CHRS $200.0m
UroGen URGN $75.0m
https://www.londonstockexchange.com/stock/BPCR/biopharma-credit-plc/company-page
